Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Devendra Hiwase, Zoe Price, Chung How Kok, Monika Kutyna, Deepak Singhal, Naranie Shanmuganathan, Lesley Rawlings, David M Ross, David T Yeung, Anna Brown, Christopher N. Hahn, Lucy Godley, Caner Saygin, Hamish S Scott

Blood (2024) 144 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2024-211795

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Danielle N Blunt, Rosemary Harrup, Gerlinda Amor, Helen Christensen, Sarah Finlayson, Frank Lin, David M Ross, Julia Dobbins, Anna Brown, Hamish S Scott, Steven W Lane

Blood (2024) 144 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2024-207463

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Blood (2023) 142 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2023-191986

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Blood (2018) 132 (9): 948–961.

https://doi.org/10.1182/blood-2018-02-832253

Published: 2018

Includes: Supplemental data

Journal Articles

Genome-Wide Analysis of Genetic Alterations In Acute Myeloid Leukaemia (Massively parallel, high-throughput, paired-end DNA sequencing and genotyping of an AML genome).

James X Gray, MD, PhD, Paul J Leo, PhD, Pamela Mukhopadhyay, PhD, Evgeny A Glazov, PhD, Patrick Danoy, PhD, Marina Donskoi, BSc, Anna Brown, PhD, Ian D. Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Matthew A Brown, MBBS, MD, Paula Marlton, MBBS, Devinder S Gill, MD, Thomas Gonda, PhD

Blood (2010) 116 (21): 1690.

https://doi.org/10.1182/blood.V116.21.1690.1690

Published: 2010

Journal Articles

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML

Blood (2009) 114 (23): 4859–4870.

https://doi.org/10.1182/blood-2009-02-204818

Published: 2009

Includes: Supplemental data

Journal Articles

The GM-CSF Receptor Utilises Members of the Canonical Wnt-Signaling Pathway during Macrophage Differentiation

Anna Brown, BSc, PhD, Diana Salerno, Christopher Wilkinson, Michelle Perugini, Chung Kok, Greg Goodall, Patricia Solomon, Thomas Gonda, Richard D’Andrea, PhD

Blood (2008) 112 (11): 3856.

https://doi.org/10.1182/blood.V112.11.3856.3856

Published: 2008

Journal Articles

Common Leukemic Signaling Pathways Identified by Comparative Analysis of GM-CSF and FLT3 Activated Receptor Mutations.

Richard D’Andrea, PhD, Michelle Perugini, BSc(Hons), Chung Kok, BSc(Hons), Christopher Wilkinson, PhD, Anna Brown, PhD, Thomas Gonda, PhD

Blood (2006) 108 (11): 1912.

https://doi.org/10.1182/blood.V108.11.1912.1912

Published: 2006

NARROW

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Genome-Wide Analysis of Genetic Alterations In Acute Myeloid Leukaemia (Massively parallel, high-throughput, paired-end DNA sequencing and genotyping of an AML genome).

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML

The GM-CSF Receptor Utilises Members of the Canonical Wnt-Signaling Pathway during Macrophage Differentiation

Common Leukemic Signaling Pathways Identified by Comparative Analysis of GM-CSF and FLT3 Activated Receptor Mutations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only